Throughout this case study, principles drove development. For A Mab, the critical quality attributes (CQAs) were:
The selected cell line, CHO-A Mab, was then adapted to grow in a serum-free medium, which is essential for large-scale production.
Commercially available ELISA kits quantified residual HCP (
| Step | Primary Goal | Key Technologies | Typical Outcome | | :--- | :--- | :--- | :--- | | | Isolate and concentrate the mAb from clarified harvest | Protein A affinity chromatography | High concentration mAb with significant impurities removed | | Intermediate Purification | Remove major impurities: HCPs, DNA, some aggregates | Ion exchange (AEX, CEX), hydrophobic interaction (HIC) | Improved purity with most process-related contaminants cleared | | Polishing | Remove remaining trace impurities and product variants | Mixed-mode chromatography, AEX, CEX in flow-through mode | Final high-purity mAb with minimal aggregates and fragments | A Mab A Case Study In Bioprocess Development
Scale-up parameters remained consistent across three consecutive 500L verification runs, demonstrating high predictability. Conclusion
The initial bioprocess for mAb-A production involved a traditional approach:
Physical, chemical, or biological properties (such as glycosylation patterns or charge variants ) that must stay within a specific range to ensure safety and efficacy. Throughout this case study, principles drove development
The bioprocess development for mAb-A illustrates the importance of innovative strategies and cutting-edge technologies in bioprocess optimization. Future directions for bioprocess development include:
Using a 0.2 cm bed height of multimodal resin (Capto Adhere) at pH 5.5.
You have the pure protein. Now, how do you store it? Proteins are fragile; they can denature (unfold) with changes in temperature or pH. You have the pure protein
: In some QbD models, real-time data can potentially replace traditional end-product testing. Summary of Key Findings
Reduced the transition from pilot to clinical scale by four months. Robustness: